Literature DB >> 1399405

Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis.

M C Callegan1, J A Hobden, J M Hill, M S Insler, R J O'Callaghan.   

Abstract

A rabbit model of Staphylococcus aureus keratitis was developed to study the chemotherapeutic efficacy of ciprofloxacin, vancomycin, and cefazolin. Intrastromal injection of 100 colony forming units of log phase S. aureus ATCC strain 25923 resulted in rapid growth in the cornea, peaking at 10(7) cfu/cornea by 12 hr post-infection. Slit-lamp examination revealed that infected eyes reached 30% of maximum inflammation by 10 hr and 60% by 22 hr post-infection. Antibiotic therapy (one drop every 15 min for 5 hr) was initiated at 4 hr post-infection (experiment 1) or 10 hr post-infection (experiment 2). Another group was initiated at 10 hr post-infection and treated for 10 hr (experiment 3). In experiment 1, treatment from 4-9 hr post-infection with 0.3% ciprofloxacin drops decreased the cfu per cornea 6.1 logs, compared to placebo-treated controls (P = 0.0001), and rendered 50% of inoculated eyes sterile. Vancomycin (5.0%) and cefazolin (5.0%) each lowered the cfu per cornea 4.6 logs (P = 0.0187) but did not sterilize any eyes. In experiment 2, therapy from 10-15 hr post-infection with 0.3% ciprofloxacin reduced the cfu per cornea 0.9 logs (P = 0.0001). Vancomycin (5.0%) and cefazolin (5.0%) decreased the cfu per cornea 0.2 logs (P = 0.3973) and 0.3 logs (P = 0.1307), respectively. In experiment 3, therapy from 10-20 hr post-infection with 0.3% ciprofloxacin reduced the cfu per cornea 3.9 logs (P < 0.0001). In this keratitis model, ciprofloxacin was more effective than vancomycin or cefazolin in killing S. aureus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1399405

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  17 in total

1.  Colonization kinetics of different methicillin-resistant Staphylococcus aureus sequence types in pigs and host susceptibilities.

Authors:  István Szabó; Britta Beck; Anika Friese; Alexandra Fetsch; Bernd-Alois Tenhagen; Uwe Roesler
Journal:  Appl Environ Microbiol       Date:  2011-11-11       Impact factor: 4.792

2.  The protective role of topical propolis on experimental keratitis via nitric oxide levels in rabbits.

Authors:  N Duran; A Koc; H Oksuz; C Tamer; Y Akaydin; T Kozlu; M Celik
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

3.  Direct translocation of staphylococci from the skin surface to deep organs.

Authors:  Beth L Hahn; Peter G Sohnle
Journal:  Microb Pathog       Date:  2013-06-05       Impact factor: 3.738

4.  The collagen-binding adhesin is a virulence factor in Staphylococcus aureus keratitis.

Authors:  M N Rhem; E M Lech; J M Patti; D McDevitt; M Höök; D B Jones; K R Wilhelmus
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

5.  A Mouse Model for Ocular Surface Staphylococcus aureus Infection.

Authors:  Zhiyong Zhang; Osama Abdel-Razek; Guirong Wang
Journal:  Curr Protoc Mouse Biol       Date:  2017-03-02

6.  Corneal virulence of Staphylococcus aureus: roles of alpha-toxin and protein A in pathogenesis.

Authors:  M C Callegan; L S Engel; J M Hill; R J O'Callaghan
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

7.  Why does the healthy cornea resist Pseudomonas aeruginosa infection?

Authors:  David J Evans; Suzanne M J Fleiszig
Journal:  Am J Ophthalmol       Date:  2013-04-17       Impact factor: 5.258

8.  Systemic dissemination and cutaneous damage in a mouse model of staphylococcal skin infections.

Authors:  Beth L Hahn; Charles C Onunkwo; Christopher J Watts; Peter G Sohnle
Journal:  Microb Pathog       Date:  2009-05-03       Impact factor: 3.738

9.  The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis.

Authors:  Mark J Mannis
Journal:  Trans Am Ophthalmol Soc       Date:  2002

10.  Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.

Authors:  Joseph J Dajcs; Brett A Thibodeaux; Mary E Marquart; Dalia O Girgis; Mullika Traidej; Richard J O'Callaghan
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.